Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.57 (market cap $69.79B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 17.7× Edgewise Therapeutics Inc. Common Stock's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.34% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 3 Days on average.
| EWTX | NWG | |
|---|---|---|
Market Cap | $3.94B | $69.79B |
Volume | 810,104 | 3,183,982 |
Sector | Health | Financials |
52-Week High | $48.35 | $19.42 |
52-Week Low | $14.89 | $13.89 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $3.48B | $142.57B |
Dividend Yield | — | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NatWest Group (NWG) trades at $17.65, up 2.38% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a low P/E of 8.94 and robust profitability with a net income margin of 36.24%. Recent earnings have consistently beaten expectations, and analyst sentiment is positive, with a 'Moderate Buy' consensus. The company has upgraded its 2026 guidance and accelerated share buybacks, supported by healthy revenue growth and improving deposit margins.
The outlook for NWG is favorable, driven by earnings momentum and supportive analyst coverage, though risks include negative cash flow trends and potential regulatory scrutiny. The stock presents a value opportunity given its attractive valuation and strong return on equity, but investors should monitor execution on profitability targets and macroeconomic impacts on the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)
NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →
